AC Immune reports full-year 2017 financial results - successful first year as a public company
Lausanne, Switzerland, March 20, 2018 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced financial results and provided a corporate overview …